Free Trial

ABVC BioPharma (ABVC) Financials

ABVC BioPharma logo
$0.94 +0.03 (+3.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for ABVC BioPharma

Annual Income Statements for ABVC BioPharma

This table shows ABVC BioPharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/18/2014 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
0.00 -11 -4.24 -7.28 -20 -13 -16 -7.79 -4.90 -7.91
Consolidated Net Income / (Loss)
0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Net Income / (Loss) Continuing Operations
0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Total Pre-Tax Income
0.00 -11 -4.24 -4.01 -11 -11 -16 -8.02 -5.37 -8.35
Total Operating Income
0.00 -11 -4.14 -3.46 -8.51 -12 -15 -6.77 -4.71 -7.15
Total Gross Profit
0.00 -0.00 0.00 0.68 0.46 0.35 0.68 -0.15 0.51 0.00
Total Revenue
0.00 0.00 0.00 0.70 0.48 0.49 1.08 0.22 0.56 0.13
Operating Revenue
0.00 0.00 0.00 0.70 0.48 0.49 1.08 0.22 0.56 0.13
Total Cost of Revenue
0.00 0.00 0.00 0.02 0.02 0.01 0.29 0.30 0.00 0.00
Operating Cost of Revenue
0.00 0.00 0.00 0.02 0.02 0.01 0.29 0.30 0.00 0.00
Total Operating Expenses
0.00 11 4.14 4.14 8.97 12 16 6.62 5.21 7.15
Selling, General & Admin Expense
- 0.60 0.81 3.07 4.27 5.75 6.07 5.37 2.26 2.89
Research & Development Expense
- 10 3.17 1.05 0.55 1.00 2.69 1.06 0.18 0.12
Other Special Charges / (Income)
- 0.40 0.16 0.02 4.15 - 7.04 0.19 2.77 4.14
Total Other Income / (Expense), net
0.00 -0.01 -0.10 -0.55 -2.31 0.36 -0.40 -1.32 -0.71 -1.34
Interest Expense
0.00 0.01 0.10 0.48 0.41 0.23 0.29 1.31 0.83 0.42
Interest & Investment Income
- 0.00 0.00 0.04 0.10 -0.23 0.18 -0.04 -0.25 -0.83
Other Income / (Expense), net
0.00 0.00 0.00 -0.11 -2.00 0.81 -0.28 0.03 0.36 -0.09
Income Tax Expense
0.00 0.00 0.00 -0.08 -0.22 0.83 0.80 0.26 -0.11 0.02
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - -0.29 -0.80 0.80 0.11 -0.49 -0.36 -0.47
Basic Earnings per Share
($0.01) ($0.06) ($0.02) ($0.21) ($0.50) ($0.51) ($5.19) ($1.80) ($0.42) ($0.39)
Weighted Average Basic Shares Outstanding
11.14K 193.98M 213.32M 17.50M 19.72M 25.05M 3.17M 4.34M 11.67M 20.11M
Diluted Earnings per Share
($0.01) ($0.06) ($0.02) ($0.21) ($0.50) - - ($1.80) ($0.42) ($0.39)
Weighted Average Diluted Shares Outstanding
11.14K 193.98M 213.32M 17.50M 19.72M 25.05M 33.08M 4.34M 11.67M 20.11M

Quarterly Income Statements for ABVC BioPharma

This table shows ABVC BioPharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-2.83 -0.94 -0.39 -0.73 -0.84 -2.26 -2.04 -3.56 -1.56 -0.74 1.15
Consolidated Net Income / (Loss)
-2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69 -0.81 -1.39
Net Income / (Loss) Continuing Operations
-2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69 -0.81 -1.39
Total Pre-Tax Income
-2.93 -1.16 -0.49 -0.80 -0.94 -2.31 -2.08 -3.81 -1.69 -0.81 -1.39
Total Operating Income
-2.84 -0.86 -0.30 -0.70 -0.69 -2.29 -1.96 -2.99 -1.57 -0.78 -1.24
Total Gross Profit
0.00 0.12 0.39 0.00 0.00 0.00 0.00 -0.80 0.00 0.00 0.00
Total Revenue
0.01 0.11 0.43 0.01 0.01 0.00 0.00 -0.69 0.01 0.00 0.00
Operating Revenue
0.01 0.11 0.43 0.01 0.01 0.00 0.00 -0.69 0.01 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
2.84 0.98 0.69 0.71 0.69 2.29 1.96 2.20 1.57 0.78 1.24
Selling, General & Admin Expense
0.74 0.65 0.56 0.31 0.62 0.69 0.80 0.78 0.75 0.50 0.38
Research & Development Expense
0.07 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02
Other Special Charges / (Income)
2.03 0.28 0.10 0.36 0.05 1.57 1.14 1.39 0.79 0.25 0.85
Total Other Income / (Expense), net
-0.10 -0.29 -0.22 -0.10 -0.26 -0.01 -0.12 -0.93 -0.13 -0.03 -0.15
Interest Expense
0.18 0.21 0.22 0.22 0.22 0.13 0.03 - 0.05 0.04 0.04
Interest & Investment Income
0.00 -0.05 -0.02 -0.18 -0.03 -0.03 -0.01 -0.76 -0.03 -0.02 -0.00
Other Income / (Expense), net
0.08 -0.03 0.02 0.29 -0.01 0.14 -0.08 -0.10 -0.05 0.04 -0.10
Income Tax Expense
0.00 -0.11 0.00 - 0.00 0.02 0.00 - 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.09 -0.11 -0.09 -0.06 -0.10 -0.08 -0.04 -0.25 -0.13 -0.07 -2.54
Basic Earnings per Share
($0.29) ($0.08) ($0.03) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06) ($0.03) $0.04
Weighted Average Basic Shares Outstanding
9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M 26.06M 26.66M
Diluted Earnings per Share
($0.29) ($0.08) ($0.03) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06) ($0.03) $0.04
Weighted Average Diluted Shares Outstanding
9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M 26.06M 26.66M
Weighted Average Basic & Diluted Shares Outstanding
10.85M 12.42M - 0.00 - - - 0.00 26.00M 26.65M 26.98M

Annual Cash Flow Statements for ABVC BioPharma

This table details how cash moves in and out of ABVC BioPharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/18/2014 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.00 -0.82 0.07 -0.08 4.84 1.59 -5.17 -0.67 0.15 0.44
Net Cash From Operating Activities
0.00 -3.47 -1.49 -3.13 -4.56 -7.60 -7.40 -4.19 -1.81 -2.99
Net Cash From Continuing Operating Activities
-0.00 -3.47 -1.49 -3.13 -4.56 -7.60 -9.03 -4.19 -1.81 -2.99
Net Income / (Loss) Continuing Operations
-0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Consolidated Net Income / (Loss)
-0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Depreciation Expense
- - - 0.06 0.04 0.01 0.02 0.03 0.03 0.03
Amortization Expense
- - - - - - - 0.35 - 0.48
Non-Cash Adjustments To Reconcile Net Income
0.00 7.77 2.62 0.12 6.59 4.54 7.36 3.12 3.83 5.48
Changes in Operating Assets and Liabilities, net
0.00 -0.24 0.13 0.63 -0.60 -0.11 -0.11 0.59 -0.41 -0.60
Net Cash From Investing Activities
0.00 0.00 0.00 -0.04 -0.23 -0.81 -1.72 -0.36 0.00 -1.21
Net Cash From Continuing Investing Activities
0.00 0.00 0.00 -0.04 -0.23 -0.81 -0.12 -0.36 0.00 -1.21
Purchase of Investments
- - - -0.04 -0.37 -0.79 - -0.34 0.00 -1.41
Other Investing Activities, net
- - - - - - - - - 0.20
Net Cash From Financing Activities
0.00 2.65 1.56 3.09 9.57 10.00 4.01 3.87 1.98 4.64
Net Cash From Continuing Financing Activities
0.00 2.65 1.56 3.09 9.57 10.00 4.01 3.87 1.98 4.64
Repayment of Debt
0.00 - 0.00 -0.86 -0.77 -0.51 0.00 -1.19 -0.36 -0.55
Repurchase of Common Equity
- - - - 0.00 -0.85 - 0.00 -0.01 0.00
Issuance of Debt
0.00 0.00 1.11 2.86 2.72 0.24 0.35 1.46 0.97 0.50
Issuance of Common Equity
- 2.35 - 0.00 7.62 11 3.66 3.46 0.43 3.31
Other Financing Activities, net
- 0.30 0.45 1.08 - - - 0.14 0.95 1.38
Cash Interest Paid
0.00 0.00 0.09 0.17 0.21 0.33 0.29 0.03 0.02 0.03
Cash Income Taxes Paid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.01

Quarterly Cash Flow Statements for ABVC BioPharma

This table details how cash moves in and out of ABVC BioPharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-0.06 0.12 0.02 0.07 -0.11 0.32 -0.23 0.46 -1.19 -0.11 -0.02
Net Cash From Operating Activities
-0.96 -0.21 0.06 -0.70 -0.54 -0.89 -0.96 -1.42 -0.89 -0.24 -0.44
Net Cash From Continuing Operating Activities
-0.96 -0.22 0.07 -0.70 -0.54 -0.89 -0.96 -1.42 -0.89 -0.24 -0.44
Net Income / (Loss) Continuing Operations
-2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69 -0.81 -1.39
Consolidated Net Income / (Loss)
-2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69 -0.81 -1.39
Depreciation Expense
0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense
0.10 - - - - 0.07 0.09 0.21 0.09 0.08 0.08
Non-Cash Adjustments To Reconcile Net Income
2.21 0.55 0.38 0.69 0.31 1.75 1.19 2.24 0.83 0.30 0.97
Changes in Operating Assets and Liabilities, net
-0.34 0.37 -0.14 -0.30 0.09 -0.39 -0.16 -0.06 -0.13 0.18 -0.11
Net Cash From Investing Activities
0.00 -0.50 0.04 0.46 0.00 -0.67 -0.51 0.73 0.05 -0.10 -0.02
Net Cash From Continuing Investing Activities
0.00 -0.50 0.04 0.46 0.00 -0.67 -0.51 0.73 0.05 -0.10 -0.02
Purchase of Investments
- - 0.04 0.46 0.00 - -0.51 0.67 -0.68 -0.14 -0.05
Other Investing Activities, net
- - - - 0.00 - - 0.20 0.73 0.03 0.02
Net Cash From Financing Activities
0.92 0.80 -0.08 0.34 0.43 1.93 1.20 1.15 -0.34 0.23 0.41
Net Cash From Continuing Financing Activities
0.92 0.80 -0.08 0.34 0.43 1.93 1.20 1.15 -0.34 0.23 0.41
Repayment of Debt
0.00 - 0.04 -0.39 -0.03 -0.07 -0.11 -0.26 -0.76 0.23 0.41
Effect of Exchange Rate Changes
-0.03 - - - - - - - - - 0.03
Cash Interest Paid
0.01 0.01 0.04 -0.04 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Cash Income Taxes Paid
0.00 0.03 -0.00 - 0.00 0.00 0.00 0.01 0.01 -0.01 -0.00

Annual Balance Sheets for ABVC BioPharma

This table presents ABVC BioPharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2014 9/30/2015 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.07 1.00 0.18 2.64 6.93 12 14 9.58 7.78 7.54 22
Total Current Assets
0.00 1.00 0.17 2.64 0.88 6.17 7.65 2.99 1.66 2.18 3.26
Cash & Equivalents
0.00 0.99 0.17 0.09 0.14 4.27 5.83 0.09 0.06 0.25 0.68
Restricted Cash
- - - 0.00 0.02 0.73 0.74 1.31 0.66 0.62 0.65
Short-Term Investments
- - - - - 0.00 0.11 0.08 0.08 0.06 0.06
Accounts Receivable
- - - 2.55 0.31 0.30 0.43 1.37 1.51 1.16 1.52
Prepaid Expenses
- 0.00 - 0.00 0.08 0.17 0.53 0.15 0.10 0.10 0.35
Other Current Assets
- - - 0.00 0.33 0.70 0.00 - - - 0.00
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.52 0.51 0.53 0.57 0.57 0.51 13
Total Noncurrent Assets
0.06 0.00 0.00 0.00 5.53 4.92 5.52 6.02 4.84 4.85 5.73
Long-Term Investments
- - - - 3.36 1.19 2.09 3.68 3.80 2.26 1.88
Other Noncurrent Operating Assets
- 0.00 0.00 - 0.70 1.94 1.63 2.22 1.04 2.59 3.85
Total Liabilities & Shareholders' Equity
0.07 1.00 0.18 2.64 6.93 12 14 9.58 7.78 7.54 22
Total Liabilities
0.03 0.37 6.56 4.40 7.05 8.94 4.83 6.34 6.53 6.82 8.52
Total Current Liabilities
0.02 0.02 6.56 4.40 6.81 4.84 3.69 5.54 6.10 6.56 6.92
Short-Term Debt
- - - 0.00 4.04 2.09 1.64 1.89 0.90 1.79 1.00
Accounts Payable
0.02 0.00 0.02 - 0.02 0.31 0.39 - 3.55 3.51 4.16
Current Deferred & Payable Income Tax Liabilities
- - - - - - - 0.00 0.11 0.00 0.01
Other Current Liabilities
- 0.02 6.50 4.23 0.73 0.32 0.35 0.74 0.83 1.26 1.75
Total Noncurrent Liabilities
0.02 0.35 0.00 0.00 0.24 4.10 1.14 0.80 0.43 0.26 1.60
Capital Lease Obligations
- - - - - - 1.12 0.79 - 0.24 1.60
Other Noncurrent Operating Liabilities
- 0.35 - 0.00 0.24 1.48 0.01 0.01 0.43 0.02 0.00
Commitments & Contingencies
- 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
0.03 0.63 -6.38 -1.76 -0.12 2.66 8.87 3.24 1.25 0.72 13
Total Preferred & Common Equity
0.03 0.63 -6.38 -1.76 -0.15 3.44 8.84 3.10 1.55 1.23 11
Preferred Stock
0.00 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
0.03 0.63 -6.38 -1.76 -0.15 3.44 8.84 3.10 1.55 1.23 11
Common Stock
0.05 1.30 4.94 14 28 41 58 68 74 79 96
Retained Earnings
-0.02 -0.32 -11 -16 -16 -26 -38 -55 -64 -69 -77
Treasury Stock
- - - - -9.10 -9.10 -9.10 -9.10 -8.90 -8.91 -8.91
Accumulated Other Comprehensive Income / (Loss)
- - - - 0.66 0.56 0.54 0.52 0.52 0.45 0.49
Other Equity Adjustments
- -0.35 - - -4.06 -3.16 -2.26 -1.35 - 0.03 0.36
Noncontrolling Interest
- - - - 0.03 -0.78 0.03 0.14 -0.30 -0.50 2.19

Quarterly Balance Sheets for ABVC BioPharma

This table presents ABVC BioPharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
17 14 15 7.78 15 16 21 20 19 20
Total Current Assets
2.49 1.79 2.19 2.17 1.47 2.77 3.31 0.65 0.41 1.40
Cash & Equivalents
0.50 0.03 0.12 0.00 0.15 0.39 0.19 0.14 0.03 0.01
Restricted Cash
0.62 0.63 0.62 0.00 0.61 0.69 0.66 0.00 0.00 0.00
Short-Term Investments
0.07 0.08 0.08 0.00 0.07 0.07 0.07 0.06 0.06 0.06
Accounts Receivable
1.16 0.90 1.26 0.00 0.54 1.42 1.93 0.33 0.14 0.93
Prepaid Expenses
0.14 0.16 0.10 0.11 0.10 0.19 0.45 0.25 0.15 0.37
Other Current Assets
- - - - - - - 0.00 0.03 0.03
Plant, Property, & Equipment, net
7.95 7.95 7.93 0.53 8.17 8.22 13 13 13 13
Total Noncurrent Assets
6.14 4.72 4.52 0.69 5.24 5.26 5.05 6.26 6.16 6.07
Long-Term Investments
4.11 3.75 3.65 0.00 3.88 3.96 2.75 1.85 2.49 2.48
Other Noncurrent Operating Assets
2.00 0.97 0.86 0.69 1.35 1.29 2.30 4.41 3.67 3.58
Total Liabilities & Shareholders' Equity
17 14 15 7.78 15 16 21 20 19 20
Total Liabilities
7.53 6.97 6.81 6.44 6.92 6.75 6.72 6.90 7.13 8.55
Total Current Liabilities
5.36 6.63 6.55 6.25 6.73 6.53 6.54 5.39 5.69 7.19
Short-Term Debt
0.85 1.70 1.80 0.90 1.64 1.13 1.03 0.89 0.30 0.27
Accounts Payable
- 4.05 3.96 3.59 3.83 4.29 3.99 4.15 4.20 4.53
Current Deferred & Payable Income Tax Liabilities
- 0.11 0.00 0.00 - 0.02 0.01 0.01 0.00 0.00
Other Current Liabilities
0.95 0.77 0.78 0.39 1.27 1.09 1.52 0.35 1.20 2.39
Total Noncurrent Liabilities
2.16 0.32 0.23 0.00 0.17 0.18 0.16 1.51 1.44 1.36
Other Noncurrent Operating Liabilities
- - - - - - - 1.51 1.44 1.36
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
9.06 7.49 7.83 1.34 7.96 9.49 14 13 12 12
Total Preferred & Common Equity
9.10 7.79 8.29 1.64 5.40 7.01 12 11 10 13
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
9.10 7.79 8.26 78 5.40 7.01 12 11 10 13
Common Stock
81 86 87 78 84 86 94 97 98 99
Retained Earnings
-62 -69 -70 0.00 -70 -72 -74 -78 -79 -77
Treasury Stock
-9.10 -8.90 -8.90 0.00 -8.91 -8.91 -8.91 -8.91 -8.91 -8.91
Accumulated Other Comprehensive Income / (Loss)
0.52 0.23 0.44 0.00 0.44 0.48 0.49 0.50 0.50 0.51
Other Equity Adjustments
-0.68 -0.23 0.00 0.00 0.03 1.09 0.64 0.42 0.11 0.11
Noncontrolling Interest
-0.04 -0.31 -0.47 -0.31 2.55 2.48 2.44 2.06 1.98 -1.31

Annual Metrics And Ratios for ABVC BioPharma

This table displays calculated financial ratios and metrics derived from ABVC BioPharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
54,593,032.00 418,705,794.00 213,746,647.00 213,926,475.00 19,478,168.00 20,813,903.00 28,609,388.00 32,632,329.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Adjusted Shares Outstanding
5,459,303.00 41,870,579.00 21,374,665.00 21,392,647.00 1,947,817.00 2,081,390.00 2,860,939.00 3,263,233.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Earnings Per Adjusted Shares Outstanding
- -0.26 -0.20 - -3.74 -9.41 -4.49 -5.03 -1.08 -0.68 -1.09
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% -31.16% 1.52% 119.62% -79.73% 155.61% -75.95%
EBITDA Growth
0.00% 0.00% 62.37% 4.73% 10.83% -197.71% -3.98% -41.25% 58.63% 32.26% -56.39%
EBIT Growth
0.00% 0.00% 62.37% 4.73% 9.43% -194.16% -3.73% -41.31% 56.22% 35.61% -66.86%
NOPAT Growth
0.00% 0.00% 62.37% 66.32% -73.65% -145.92% -37.62% -29.12% 55.23% 30.47% -51.98%
Net Income Growth
0.00% 0.00% 61.46% 6.67% 0.00% -169.33% -13.61% -35.53% 49.24% 36.49% -59.29%
EPS Growth
0.00% 0.00% 66.67% 0.00% 0.00% -138.10% 0.00% 0.00% 0.00% 76.67% 7.14%
Operating Cash Flow Growth
187.67% 0.00% 57.25% 57.57% 0.00% -45.60% -66.47% 2.62% 43.41% 56.79% -65.07%
Free Cash Flow Firm Growth
101.26% -2,518.66% -563.45% 140.29% -370.00% 29.87% -46.64% 14.28% 73.36% -102.04% -260.89%
Invested Capital Growth
-100.00% 0.00% 71.76% -267.87% 105.73% 202.82% 143.68% -73.10% -320.41% 74.41% 2,626.86%
Revenue Q/Q Growth
0.00% 0.00% 100.00% 0.00% 0.00% -7.25% -5.52% 128.51% -73.10% -5.42% 98.38%
EBITDA Q/Q Growth
100.00% 0.00% 68.68% -895.35% 0.00% -60.02% -8.39% 13.69% 34.21% 0.40% -26.56%
EBIT Q/Q Growth
100.00% 0.00% 58.95% -830.07% 0.00% -59.58% -8.34% 13.65% 30.47% 0.33% -35.28%
NOPAT Q/Q Growth
100.00% 0.00% 6.04% -218.90% 0.00% -77.98% -15.79% 17.98% 27.92% -4.27% -26.42%
Net Income Q/Q Growth
0.00% 0.00% 4.84% -391.24% 0.00% -57.17% -19.12% 12.83% 31.46% -1.86% -36.06%
EPS Q/Q Growth
0.00% 0.00% 33.33% 166.30% 0.00% 0.00% 0.00% 0.00% 40.59% -13.51% -56.00%
Operating Cash Flow Q/Q Growth
-3.95% 0.00% 6.48% 96.70% 0.00% -17.88% -4.64% 21.81% 0.73% -17.67% 3.69%
Free Cash Flow Firm Q/Q Growth
100.83% -117.48% 10.96% 2,279.67% -363.89% -111.46% 8.65% 30.09% 78.21% -172.85% 11.59%
Invested Capital Q/Q Growth
-100.00% -0.69% -75.19% -515.31% 129.08% 8,150.62% -23.59% -74.12% -125.15% 83.49% -8.32%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 97.13% 96.13% 71.52% 63.46% -68.52% 91.18% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% -501.06% -2,167.02% -2,219.61% -1,427.59% -2,913.15% -772.01% -5,020.73%
Operating Margin
0.00% 0.00% 0.00% 0.00% -492.90% -1,760.87% -2,387.16% -1,403.47% -3,099.31% -843.13% -5,328.97%
EBIT Margin
0.00% 0.00% 0.00% 0.00% -508.91% -2,174.71% -2,222.05% -1,429.80% -3,087.37% -777.75% -5,396.92%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% -560.52% -2,193.08% -2,454.43% -1,514.71% -3,792.81% -942.37% -6,242.33%
Tax Burden Percent
0.00% 100.01% 100.02% 200.09% 98.08% 97.96% 107.36% 105.14% 103.19% 97.94% 100.29%
Interest Burden Percent
0.00% 100.09% 102.50% 207.93% 112.30% 102.94% 102.89% 100.76% 119.05% 123.71% 115.33%
Effective Tax Rate
0.00% 0.00% 0.00% -0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -758.53% -404.05% -579.82% 0.00% 0.00% -94.57%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 200.69% -301.28% -444.26% 0.00% 0.00% 101.74%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% -76.52% 195.32% 310.34% 0.00% 0.00% -24.92%
Return on Equity (ROE)
0.00% 383.16% 104.30% 115.57% 6,302.41% -835.04% -208.73% -269.48% -368.89% -531.91% -119.49%
Cash Return on Invested Capital (CROIC)
200.00% 0.00% 0.00% 0.00% -2,467.75% -859.23% -487.66% -464.61% 0.00% 0.00% -149.37%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% -103.09% -113.35% -86.12% -132.30% -77.64% -56.65% -50.64%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% -113.55% -114.31% -95.13% -140.16% -95.38% -68.64% -58.58%
Return on Common Equity (ROCE)
0.00% 383.16% 104.30% 241.49% 7,622.66% -1,081.92% -222.30% -265.83% -382.29% -747.85% -105.14%
Return on Equity Simple (ROE_SIMPLE)
0.00% 172.56% 241.49% 72.49% 2,605.42% -308.10% -136.10% -526.45% -532.84% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
0.00 -7.70 -2.90 -1.39 -2.42 -5.95 -8.19 -11 -4.74 -3.29 -5.01
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -345.03% -1,232.61% -1,671.01% -982.43% -2,169.52% -590.19% -3,730.28%
Net Nonoperating Expense Percent (NNEP)
0.00% -3,814.39% -1,008.54% -531.81% -317.79% -959.22% -102.77% -135.56% -130.75% -95.44% -196.31%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -220.03% -119.72% -35.02%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 2.87% 3.87% 1.04% 26.60% 138.34% 0.14% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 437.42% 884.69% 1,171.79% 563.41% 2,458.79% 405.21% 2,151.60%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 149.43% 113.79% 204.70% 250.10% 486.84% 32.12% 90.23%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 590.03% 1,856.99% 2,458.68% 1,477.15% 3,030.79% 934.31% 5,328.97%
Earnings before Interest and Taxes (EBIT)
0.00 -11 -4.14 -3.94 -3.57 -11 -11 -15 -6.74 -4.34 -7.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.00 -11 -4.14 -3.94 -3.52 -10 -11 -15 -6.36 -4.31 -6.74
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 14.05 9.60 66.73 3.24 5.62 3.85
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 14.05 9.60 66.73 3.24 5.62 3.85
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 108.97 100.00 173.20 191.98 23.04 12.34 319.18
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% -2.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 197.60 39.02 27.46 264.28 0.00 0.00 3.88
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 109.74 95.32 161.03 189.83 4.71 9.36 318.51
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 114.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 -0.42 -32.36 1.77 0.31 0.83 0.72 2.80 0.07
Long-Term Debt to Equity
0.00 0.00 0.00 -0.10 0.00 0.99 0.13 0.24 0.00 0.33 0.00
Financial Leverage
0.51 0.03 0.03 0.22 7.62 -0.38 -0.65 -0.70 -1.21 -2.08 -0.24
Leverage Ratio
2.09 -0.21 -0.35 -2.42 -55.50 7.31 2.19 1.92 3.87 7.75 2.04
Compound Leverage Factor
0.00 -0.21 -0.36 -2.51 -62.33 7.52 2.26 1.94 4.60 9.59 2.35
Debt to Total Capital
0.00% 0.00% 0.00% -147.27% 103.19% 63.89% 23.76% 45.35% 41.77% 73.68% 6.97%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% -130.03% 103.19% 28.29% 14.10% 31.98% 41.77% 65.08% 6.97%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% -17.25% 0.00% 35.60% 9.67% 13.37% 0.00% 8.61% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% -10.33% 0.67% -10.53% 0.23% 2.32% -13.97% -18.25% 15.29%
Common Equity to Total Capital
0.00% 100.00% 100.00% 367.93% -3.86% 46.64% 76.01% 52.33% 72.19% 44.57% 77.74%
Debt to EBITDA
0.00 0.00 0.00 -1.15 -1.15 -0.45 -0.25 -0.17 -0.14 -0.47 -0.15
Net Debt to EBITDA
0.00 0.00 0.00 0.74 -0.15 0.14 0.55 0.16 0.58 0.27 0.34
Long-Term Debt to EBITDA
0.00 0.00 0.00 -0.07 0.00 -0.25 -0.10 -0.05 0.00 -0.06 0.00
Debt to NOPAT
0.00 0.00 0.00 -3.25 -1.67 -0.79 -0.34 -0.25 -0.19 -0.62 -0.20
Net Debt to NOPAT
0.00 0.00 0.00 1.05 -0.21 0.25 0.73 0.23 0.78 0.35 0.45
Long-Term Debt to NOPAT
0.00 0.00 0.00 -0.38 0.00 -0.44 -0.14 -0.07 0.00 -0.07 0.00
Altman Z-Score
0.00 -336.57 -13.38 29.29 0.67 -2.66 4.38 6.02 -14.57 -14.72 -3.14
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% -4.48% -20.95% -29.56% -6.50% 1.36% -3.63% -40.60% 12.01%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 0.03 0.60 0.10 0.13 1.27 2.07 0.54 0.27 0.33 0.41
Quick Ratio
0.00 0.03 0.60 0.05 0.07 0.94 1.72 0.28 0.27 0.22 0.24
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.05 -1.15 -7.60 3.56 -9.62 -6.74 -9.89 -8.48 -2.26 -4.56 -16
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -43,408.10% -6,181.19% -19,748.35% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -112.63 -73.45 22.84 -19.95 -16.65 -43.53 -28.84 -1.72 -5.52 -39.59
Operating Cash Flow to Interest Expense
0.00 -341.66 -14.36 -4.04 -6.50 -11.27 -33.44 -25.17 -3.19 -2.19 -7.18
Operating Cash Flow Less CapEx to Interest Expense
0.00 -341.66 -14.36 -8.08 -6.50 -11.27 -33.52 -25.57 -3.20 -2.19 -7.18
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.20 0.05 0.04 0.09 0.03 0.07 0.01
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 1.58 1.34 1.20 0.15 0.42 0.14
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.93 0.94 1.96 0.38 1.03 0.02
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.11 0.01 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 230.46 271.40 304.28 2,404.54 870.59 2,608.98
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 3,271.31 25,294.26 0.00 0.00 1,688,130.74 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 -3,040.85 -25,022.87 304.28 2,404.54 -1,687,260.15 2,608.98
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 -6.55 -1.85 -6.81 0.39 1.18 2.88 0.77 -1.70 -0.44 11
Invested Capital Turnover
0.00 0.00 0.00 0.00 -0.22 0.62 0.24 0.59 -0.47 -0.52 0.03
Increase / (Decrease) in Invested Capital
-0.05 -6.55 4.70 -4.96 7.20 0.79 1.70 -2.10 -2.48 1.27 11
Enterprise Value (EV)
0.00 6.70 6.78 818 77 46 79 204 1.03 5.23 43
Market Capitalization
0.00 6.88 6.88 410 76 48 85 207 5.03 6.89 43
Book Value per Share
$0.00 ($0.03) ($0.01) ($0.03) ($0.01) $0.17 $0.31 $0.10 $0.21 $0.11 $0.55
Tangible Book Value per Share
$0.00 ($0.03) ($0.01) ($0.03) ($0.01) $0.17 $0.31 $0.10 $0.21 $0.11 $0.55
Total Capital
0.00 -6.38 -1.76 -3.08 3.91 7.37 12 5.92 2.15 2.75 14
Total Debt
0.00 0.00 0.00 2.26 4.04 4.71 2.76 2.69 0.90 2.03 1.00
Total Long-Term Debt
0.00 0.00 0.00 0.27 0.00 2.62 1.12 0.79 0.00 0.24 0.00
Net Debt
0.00 -0.17 -0.09 -1.47 0.51 -1.48 -5.99 -2.46 -3.70 -1.16 -2.27
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.12 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -6.56 -1.85 -8.66 -2.06 -1.59 -1.07 -2.13 -4.34 -3.52 -4.06
Debt-free Net Working Capital (DFNWC)
0.00 -6.38 -1.76 -8.42 -1.90 3.41 5.60 -0.66 -3.55 -2.59 -2.67
Net Working Capital (NWC)
0.00 -6.38 -1.76 -10 -5.94 1.33 3.96 -2.56 -4.45 -4.38 -3.66
Net Nonoperating Expense (NNE)
0.00 3.31 1.35 2.71 1.51 4.64 3.84 5.73 3.54 1.97 3.37
Net Nonoperating Obligations (NNO)
0.00 -0.17 -0.09 -1.47 0.51 -1.48 -5.99 -2.46 -2.96 -1.16 -2.27
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.06 0.04 0.01 0.02 0.38 0.03 0.50
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -293.11% -328.54% -218.59% -197.80% -1,988.74% -630.01% -3,024.28%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -270.24% 706.84% 1,142.29% -61.53% -1,624.11% -463.63% -1,987.48%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% -845.92% 275.04% 807.85% -237.38% -2,035.99% -784.43% -2,729.32%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) ($5.20) ($2.43) ($0.42) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 11.39M 0.00 2.44M 3.03M 3.17M 4.34M 11.67M 20.11M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) $0.00 $0.00 ($0.42) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 11.39M 0.00 2.44M 3.03M 3.31M 10.56M 11.67M 20.11M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 11.88M 0.00 1.97M 2.51M 3.31M 10.56M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
0.00 -7.42 -2.79 -0.96 -2.41 -3.05 -8.19 -5.58 -4.61 -1.35 -2.11
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -342.80% -631.65% -1,671.01% -517.88% -2,109.91% -242.31% -1,569.28%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% -571.49% -2,238.70% -2,286.18% -1,440.63% -3,675.55% -962.17% -6,224.33%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 -1,081.33 -40.00 -50.57 -7.41 -25.94 -47.96 -52.38 -5.13 -5.26 -17.41
NOPAT to Interest Expense
0.00 -756.94 -28.00 -17.88 -5.02 -14.70 -36.06 -35.99 -3.61 -3.99 -12.04
EBIT Less CapEx to Interest Expense
0.00 -1,081.33 -40.00 -50.57 -7.41 -25.94 -48.03 -52.79 -5.15 -5.26 -17.41
NOPAT Less CapEx to Interest Expense
0.00 -756.94 -28.00 -17.88 -5.02 -14.70 -36.14 -36.40 -3.62 -3.99 -12.04
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.07% 0.00% 0.00% -0.14% 0.00%

Quarterly Metrics And Ratios for ABVC BioPharma

This table displays calculated financial ratios and metrics derived from ABVC BioPharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 26,000,442.00 26,654,365.00
DEI Adjusted Shares Outstanding
7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 26,000,442.00 26,654,365.00
DEI Earnings Per Adjusted Shares Outstanding
-0.39 -0.13 -0.05 -0.10 -0.12 -0.31 -0.28 -0.49 -0.22 -0.03 0.04
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-93.88% 1,694.40% 2,577.39% -69.62% 30.36% -89.05% -93.02% -5,010.17% 0.00% 0.00% 0.00%
EBITDA Growth
-39.11% 60.10% 87.54% 4.14% 73.85% -137.36% -627.44% -618.63% -120.73% 69.52% 35.68%
EBIT Growth
-43.99% 59.62% 87.26% 3.40% 74.57% -142.88% -643.57% -652.45% -131.66% 65.46% 34.38%
NOPAT Growth
-48.90% 60.79% 85.97% -37.65% 75.58% -166.83% -549.77% -325.07% -126.91% 66.03% 36.84%
Net Income Growth
-54.31% 54.76% 85.53% -13.74% 67.75% -122.72% -327.44% -378.63% -78.98% 65.26% 33.28%
EPS Growth
0.00% 0.00% 96.34% 33.33% 79.31% -62.50% -200.00% -150.00% 0.00% 76.92% 144.44%
Operating Cash Flow Growth
36.18% 76.50% 104.43% -63.11% 43.52% -322.93% -1,701.71% -102.10% -65.65% 72.67% 54.50%
Free Cash Flow Firm Growth
-500.10% -243.12% 273.82% -183.10% 91.42% 70.47% -274.16% -669.38% -1,435.01% -152.77% 110.56%
Invested Capital Growth
378.03% 1,164.83% -138.97% 74.41% 0.53% 5.74% 555.10% 2,626.86% 133.71% 75.52% -21.31%
Revenue Q/Q Growth
-79.97% 1,090.87% 287.95% -96.72% -14.08% 0.00% 147.33% -2,410.49% 101.75% -100.00% 0.00%
EBITDA Q/Q Growth
-534.71% 66.92% 69.04% -47.45% -73.14% -254.94% 5.11% -45.66% 46.82% 57.29% -91.52%
EBIT Q/Q Growth
-547.49% 67.67% 68.71% -47.48% -70.46% -208.81% 4.21% -49.24% 47.52% 54.21% -80.37%
NOPAT Q/Q Growth
-454.53% 69.70% 64.85% -133.06% 1.64% -231.16% 14.41% -52.46% 47.49% 50.43% -59.15%
Net Income Q/Q Growth
-318.05% 64.22% 53.46% -63.41% -18.54% -147.07% 10.69% -82.98% 55.67% 52.04% -71.52%
EPS Q/Q Growth
-222.22% 72.41% 62.50% -100.00% 0.00% -116.67% 30.77% -66.67% 60.00% 50.00% 233.33%
Operating Cash Flow Q/Q Growth
-122.04% 77.88% 128.49% -1,265.75% 23.12% -65.64% -7.89% -47.09% 36.98% 72.67% -79.58%
Free Cash Flow Firm Q/Q Growth
-381.10% -8.84% 241.97% -119.13% 70.96% -274.38% -737.35% 15.49% 42.06% 38.35% 134.98%
Invested Capital Q/Q Growth
394.68% 7.08% -149.11% 83.49% 1,257.78% 12.63% 111.35% -8.32% 7.08% -15.41% -5.25%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
10.08% 106.69% 91.47% 14.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-28,848.39% -801.39% -63.96% -2,871.76% -5,786.63% -17,376.53% -6,666.81% 0.00% -12,772.94% 0.00% 0.00%
Operating Margin
-30,833.84% -784.63% -71.09% -5,044.85% -5,775.04% -19,124.86% -6,618.46% 0.00% -13,103.93% 0.00% 0.00%
EBIT Margin
-29,962.41% -813.53% -65.61% -2,946.37% -5,845.14% -18,050.13% -6,990.29% 0.00% -13,540.91% 0.00% 0.00%
Profit (Net Income) Margin
-31,805.18% -955.49% -114.62% -5,703.33% -7,868.25% -19,440.28% -7,019.79% 0.00% -14,082.81% 0.00% 0.00%
Tax Burden Percent
100.00% 90.43% 100.07% 100.00% 100.00% 101.02% 100.03% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
106.15% 129.89% 174.56% 193.57% 134.61% 106.61% 100.40% 123.13% 104.00% 108.92% 103.58%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-548.28% -40.72% -14.19% 0.00% -450.09% -1,120.60% -66.81% 0.00% -146.07% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-488.48% -6.28% -5.38% 0.00% -432.99% -1,097.35% -44.85% 0.00% -116.08% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
166.66% 2.18% 3.24% 0.00% 150.52% 396.01% 18.28% 0.00% 21.95% 0.00% 0.00%
Return on Equity (ROE)
-381.62% -38.54% -10.95% -531.91% -299.58% -724.59% -48.54% 0.00% -124.12% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)
-308.21% -192.21% 0.00% 0.00% -36.10% -56.11% -154.91% -149.37% -146.84% -113.02% -13.89%
Operating Return on Assets (OROA)
-183.53% -12.27% -3.18% -214.60% -223.50% -541.64% -32.62% 0.00% -105.01% 0.00% 0.00%
Return on Assets (ROA)
-194.81% -14.41% -5.55% -415.39% -300.86% -583.36% -32.76% 0.00% -109.21% 0.00% 0.00%
Return on Common Equity (ROCE)
-391.60% -40.72% -92.01% -747.85% -255.99% -639.15% -276.89% 0.00% -96.60% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)
-119.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.99 -0.60 -0.21 -0.49 -0.49 -1.61 -1.38 -2.10 -1.10 -0.55 -0.87
NOPAT Margin
-21,583.69% -549.24% -49.76% -3,531.40% -4,042.53% -13,387.40% -4,632.92% 0.00% -9,172.75% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-59.81% -34.43% -8.81% -14.73% -17.10% -23.24% -21.96% -99.93% -29.98% -8.70% -21.95%
Return On Investment Capital (ROIC_SIMPLE)
-20.89% -6.11% -9.48% -17.93% -4.97% -14.88% -8.77% -14.67% -8.03% -4.34% -7.23%
Cost of Revenue to Revenue
3.01% 0.17% 0.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
8,022.66% 596.41% 131.11% 2,230.21% 5,128.09% 5,750.78% 2,689.53% 0.00% 6,266.65% 0.00% 0.00%
R&D to Revenue
750.31% 36.86% 8.89% 228.98% 240.51% 277.30% 100.71% 0.00% 275.83% 0.00% 0.00%
Operating Expenses to Revenue
30,843.92% 891.31% 162.55% 5,058.93% 5,775.04% 19,124.86% 6,618.46% 0.00% 13,103.93% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.76 -0.89 -0.28 -0.41 -0.70 -2.17 -2.07 -3.10 -1.62 -0.74 -1.34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.66 -0.88 -0.27 -0.40 -0.69 -2.09 -1.98 -2.88 -1.53 -0.65 -1.25
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.64 1.06 0.11 5.62 2.94 5.52 5.86 3.85 2.29 4.00 2.17
Price to Tangible Book Value (P/TBV)
1.64 1.06 0.11 5.62 2.94 5.52 5.86 3.85 2.29 4.00 2.17
Price to Revenue (P/Rev)
165.29 48.50 14.37 12.34 28.29 83.51 1,045.15 319.18 183.97 306.81 210.56
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.99 1.09 0.00 0.00 3.07 6.57 5.88 3.88 2.17 4.09 2.61
Enterprise Value to Revenue (EV/Rev)
129.42 32.43 15.37 9.36 27.66 80.65 1,044.60 318.51 190.64 304.56 183.81
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 1.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.27 0.26 0.67 2.80 0.23 0.14 0.08 0.07 0.07 0.02 0.02
Long-Term Debt to Equity
0.04 0.03 0.00 0.33 0.02 0.02 0.01 0.00 0.00 0.00 0.00
Financial Leverage
-0.34 -0.35 -0.60 -2.08 -0.35 -0.36 -0.41 -0.24 -0.19 -0.28 -0.18
Leverage Ratio
2.73 3.21 2.34 7.75 1.90 1.78 1.83 2.04 1.67 1.64 1.58
Compound Leverage Factor
2.90 4.17 4.09 15.00 2.56 1.90 1.84 2.51 1.73 1.78 1.64
Debt to Total Capital
21.26% 20.61% 40.13% 73.68% 18.48% 12.08% 7.60% 6.97% 6.47% 2.38% 2.25%
Short-Term Debt to Total Capital
17.91% 18.29% 40.13% 65.08% 16.77% 10.43% 6.55% 6.97% 6.47% 2.38% 2.25%
Long-Term Debt to Total Capital
3.35% 2.32% 0.00% 8.61% 1.71% 1.64% 1.05% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-3.21% -4.72% -13.66% -18.25% 26.15% 22.94% 15.52% 15.29% 14.99% 15.77% -10.90%
Common Equity to Total Capital
81.95% 83.79% 3,504.16% 44.57% 55.37% 64.98% 76.88% 77.74% 78.54% 81.85% 108.65%
Debt to EBITDA
-0.27 -0.33 -0.21 -0.47 -0.80 -0.37 -0.22 -0.15 -0.11 -0.05 -0.05
Net Debt to EBITDA
0.33 0.39 -0.21 0.27 1.29 1.08 0.46 0.34 0.14 0.36 0.41
Long-Term Debt to EBITDA
-0.04 -0.04 0.00 -0.06 -0.07 -0.05 -0.03 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.38 -0.46 -0.28 -0.62 -1.01 -0.47 -0.30 -0.20 -0.16 -0.07 -0.07
Net Debt to NOPAT
0.46 0.55 -0.28 0.35 1.62 1.36 0.62 0.45 0.21 0.50 0.56
Long-Term Debt to NOPAT
-0.06 -0.05 0.00 -0.07 -0.09 -0.06 -0.04 0.00 0.00 0.00 0.00
Altman Z-Score
-6.64 -6.51 0.12 -13.00 -5.73 -3.46 0.92 -2.49 -3.97 -2.69 -3.90
Noncontrolling Interest Sharing Ratio
-2.61% -5.65% -740.07% -40.60% 14.55% 11.79% -470.45% 0.00% 22.17% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.27 0.33 0.35 0.33 0.22 0.42 0.51 0.41 0.12 0.07 0.20
Quick Ratio
0.15 0.22 0.00 0.22 0.11 0.29 0.33 0.24 0.10 0.04 0.14
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-5.96 -6.49 9.21 -1.76 -0.51 -1.92 -16 -14 -7.85 -4.84 1.69
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-32.81 -31.33 41.78 -8.13 -2.29 -14.80 -518.10 0.00 -159.06 -114.40 38.80
Operating Cash Flow to Interest Expense
-5.26 -1.02 0.27 -3.24 -2.42 -6.91 -31.16 0.00 -18.11 -5.77 -10.06
Operating Cash Flow Less CapEx to Interest Expense
-5.26 -1.02 0.27 -3.24 -2.42 -6.91 -31.16 0.00 -18.11 -5.77 -10.06
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.01 0.02 0.05 0.07 0.04 0.03 0.00 0.01 0.01 0.01 0.01
Accounts Receivable Turnover
0.09 0.19 0.00 0.42 0.78 0.35 0.00 0.14 0.31 0.17 0.09
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.02 0.04 0.14 1.03 0.07 0.06 0.01 0.02 0.01 0.01 0.01
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
3,884.14 1,914.60 0.00 870.59 467.60 1,056.70 0.00 2,608.98 1,182.42 2,119.82 3,900.76
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 1,688,130.74 2,958,176.30 5,087,812.69 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
3,884.14 1,914.60 0.00 -1,687,260.15 -2,957,708.69 -5,086,755.98 0.00 2,608.98 1,182.42 2,119.82 3,900.76
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
5.02 5.38 -2.64 -0.44 5.05 5.69 12 11 12 9.98 9.46
Invested Capital Turnover
0.03 0.07 0.29 -0.52 0.11 0.08 0.01 0.03 0.02 0.02 0.01
Increase / (Decrease) in Invested Capital
3.97 5.88 -9.42 1.27 0.03 0.31 15 11 6.75 4.30 -2.56
Enterprise Value (EV)
9.99 5.86 9.07 5.23 16 37 71 43 26 41 25
Market Capitalization
13 8.76 8.48 6.89 16 39 71 43 25 41 28
Book Value per Share
$0.80 $0.73 $6.31 $0.11 $0.36 $0.40 $0.52 $0.55 $0.42 $0.40 $0.49
Tangible Book Value per Share
$0.80 $0.73 $6.31 $0.11 $0.36 $0.40 $0.52 $0.55 $0.42 $0.40 $0.49
Total Capital
9.51 9.86 2.23 2.75 9.76 11 16 14 14 13 12
Total Debt
2.02 2.03 0.90 2.03 1.80 1.30 1.19 1.00 0.89 0.30 0.27
Total Long-Term Debt
0.32 0.23 0.00 0.24 0.17 0.18 0.16 0.00 0.00 0.00 0.00
Net Debt
-2.46 -2.44 0.90 -1.16 -2.91 -3.80 -2.47 -2.27 -1.16 -2.28 -2.28
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-3.87 -3.37 -3.18 -3.52 -4.45 -3.78 -3.12 -4.06 -4.06 -5.08 -5.58
Debt-free Net Working Capital (DFNWC)
-3.14 -2.56 -3.18 -2.59 -3.62 -2.64 -2.20 -2.67 -3.86 -4.98 -5.52
Net Working Capital (NWC)
-4.84 -4.36 -4.08 -4.38 -5.26 -3.76 -3.23 -3.66 -4.74 -5.28 -5.79
Net Nonoperating Expense (NNE)
0.94 0.45 0.28 0.30 0.46 0.73 0.71 1.72 0.59 0.26 0.52
Net Nonoperating Obligations (NNO)
-2.46 -2.45 -3.98 -1.16 -2.91 -3.80 -2.47 -2.27 -1.02 -2.28 -2.28
Total Depreciation and Amortization (D&A)
0.10 0.01 0.01 0.01 0.01 0.08 0.10 0.21 0.09 0.09 0.09
Debt-free, Cash-free Net Working Capital to Revenue
-5,016.35% -1,867.41% -538.82% -630.01% -793.22% -815.45% -4,615.34% -3,024.28% -3,024.71% -3,783.78% -4,161.54%
Debt-free Net Working Capital to Revenue
-4,063.93% -1,414.41% -538.82% -463.63% -646.19% -569.03% -3,256.67% -1,987.48% -2,873.81% -3,713.46% -4,112.02%
Net Working Capital to Revenue
-6,271.35% -2,412.83% -690.71% -784.43% -938.05% -812.13% -4,776.19% -2,729.32% -3,535.34% -3,936.61% -4,313.22%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.40) ($0.09) ($0.02) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06) ($0.03) $0.04
Adjusted Weighted Average Basic Shares Outstanding
9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M 26.06M 26.66M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.02) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06) ($0.03) $0.04
Adjusted Weighted Average Diluted Shares Outstanding
10.85M 12.42M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M 26.06M 26.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.06) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
10.85M 12.42M 0.00 0.00 0.00 0.00 0.00 0.00 26.00M 26.65M 26.98M
Normalized Net Operating Profit after Tax (NOPAT)
-0.56 -0.40 -0.14 -0.24 -0.45 -0.51 -0.58 -1.13 -0.55 -0.37 -0.28
Normalized NOPAT Margin
-6,134.02% -368.60% -33.98% -1,711.58% -3,758.02% -4,219.66% -1,953.17% 0.00% -4,579.74% 0.00% 0.00%
Pre Tax Income Margin
-31,805.18% -1,056.66% -114.53% -5,703.33% -7,868.25% -19,243.38% -7,018.01% 0.00% -14,082.81% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-15.18 -4.31 -1.27 -1.90 -3.15 -16.74 -67.02 0.00 -32.91 -17.58 -30.75
NOPAT to Interest Expense
-10.94 -2.91 -0.96 -2.28 -2.18 -12.41 -44.42 0.00 -22.29 -12.89 -19.90
EBIT Less CapEx to Interest Expense
-15.18 -4.31 -1.27 -1.90 -3.15 -16.74 -67.02 0.00 -32.91 -17.58 -30.75
NOPAT Less CapEx to Interest Expense
-10.94 -2.91 -0.96 -2.28 -2.18 -12.41 -44.42 0.00 -22.29 -12.89 -19.90
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -0.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ABVC BioPharma’s second-quarter 2026 statements show a sequential reduction in losses and cash burn, but the company remains financially fragile. Revenue fell to zero in Q2 2026 from $12,000 in Q1 and $29,680 in Q3 2025. ABVC continues to report substantial operating expenses, including $503,778 in selling, general and administrative costs and $253,041 in special charges.

  • Quarterly net loss improved. Net loss attributable to common shareholders narrowed to $736,934 in Q2 2026 from $1.56 million in Q1 2026 and $3.56 million in Q4 2025.
  • Operating cash burn also improved. Cash used in operating activities declined to $244,413 in Q2 2026 from $894,243 in Q1 and $1.42 million in Q4 2025.
  • Debt declined sequentially. Short-term debt fell to $299,462 at June 30, 2026, from $887,747 at March 31 and $1.03 million at September 30, 2025. The company also reported a $226,209 financing cash inflow in Q2, primarily related to debt repayment activity as classified in the statement.
  • Accounts receivable decreased substantially. Receivables fell to $136,344 in Q2 2026 from $332,338 in Q1 and $1.93 million in Q3 2025, which could reduce working-capital pressure if the balances are collected.
  • Investment balances provide some financial resources. Short- and long-term investments totaled approximately $2.55 million at the end of Q2 2026, although their liquidity and ability to fund operations are not clear from the provided statements.
  • Losses have been recurring for several years. ABVC reported net losses in every provided quarterly income statement from Q3 2023 through Q2 2026, although the size of the losses has fluctuated considerably.
  • Revenue generation remains extremely weak. Quarterly revenue declined from $425,276 in Q3 2024 to $13,966 in Q4 2024, $12,000 in Q1 2025, and zero in Q2 2025. Revenue briefly reached $29,680 in Q3 2025 and $12,000 in Q1 2026 before returning to zero in Q2 2026.
  • Liquidity is severely strained. Cash and equivalents were only $31,944 at June 30, 2026, compared with $5.69 million of current liabilities. Including short-term investments, immediately available current financial assets were approximately $94,000, leaving a very large gap relative to near-term obligations.
  • Accounts payable remains exceptionally high. Accounts payable totaled $4.20 million in Q2 2026, representing the majority of current liabilities and more than 130 times the company’s reported cash balance.
  • Equity financing has increased dilution risk. Weighted-average basic shares outstanding rose to 26.1 million in Q2 2026 from 25.4 million in Q1 and 17.4 million in Q2 2025. Common stock on the balance sheet also increased over the period, while retained earnings remained deeply negative at approximately $79.2 million.

Overall, the latest quarter contains some modest improvements in expenses, net losses, debt and operating cash flow. However, those improvements were not accompanied by meaningful revenue, and ABVC’s minimal cash balance, large accounts payable balance and dependence on external financing remain significant risks for investors.

11/16/26 03:51 PM ETAI Generated. May Contain Errors.

ABVC BioPharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ABVC BioPharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ABVC BioPharma's net income appears to be on a downward trend, with a most recent value of -$8.38 million in 2025, compared with $0.00 in 2014. The previous period was -$5.26 million in 2024. Find out what analysts predict for ABVC BioPharma in the coming months.

ABVC BioPharma's total operating income in 2025 was -$7.15 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $7.15 million

Over the last 11 years, ABVC BioPharma's total revenue changed from $0.00 in 2014 to $134.20 thousand in 2025, a change of 13,419,600.0%.

In the past 12 quarters, ABVC BioPharma's cash and equivalents has ranged from $0.00 in Q3 2024 to $500.07 thousand in Q3 2023, and is currently $11.29 thousand as of their latest financial filing in Q3 2026.

ABVC BioPharma had total debt of $995.51 thousand at the end of 2025, a 50.9% decrease from 2024, and none in 2015.

Over the last 10 years, ABVC BioPharma's book value per share changed from 0.00 in 2015 to 0.55 in 2025, a change of 55.3%.



Financial statements for NASDAQ:ABVC last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners